Loading
Cusatuzumab is an experimental monoclonal antibody from OncoVerity in phase 2 trials for acute myeloid leukaemia, aimed at CD70.
Cusatuzumab (OV-1001, JNJ-74494550, ARGX-110) is a monoclonal antibody developed by OncoVerity. Its target is CD70. ClinicalTrials.gov describes the intervention as: Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in acute myeloid leukaemia. The largest, NCT06384261, plans to enrol 140 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Monoclonal antibody directed at CD70, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to CD70.
1.Cusatuzumab binds CD70.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Cusatuzumab" OR ABSTRACT:"Cusatuzumab" OR TITLE:"OV-1001" OR ABSTRACT:"OV-1001" OR TITLE:"JNJ-74494550" OR ABSTRACT:"JNJ-74494550" OR TITLE:"ARGX-110" OR ABSTRACT:"ARGX-110") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cusatuzumab, not a curated reading list.
Shares CD70 and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.